

浏览全部资源
扫码关注微信
1.北京中医药大学 中药学院,北京 102488
2.中财瀚熙(北京)生物科技发展有限公司,北京 101503
3.北京大学 药学院 天然药物及仿生药物国家重点实验室,北京 100191
Received:10 November 2020,
Published Online:12 January 2021,
Published:20 July 2021
移动端阅览
杨海洋,汪国鹏,杨文宁等.黄芩素、槲皮素、高良姜素对黄嘌呤氧化酶靶点占有率的模拟分析[J].中国实验方剂学杂志,2021,27(14):147-154.
YANG Hai-yang,WANG Guo-peng,YANG Wen-ning,et al.Simulation Analysis of Occupancy Rates of Baicalein, Quercetin and Galangin on Target Sites of Xanthine Oxidase[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(14):147-154.
杨海洋,汪国鹏,杨文宁等.黄芩素、槲皮素、高良姜素对黄嘌呤氧化酶靶点占有率的模拟分析[J].中国实验方剂学杂志,2021,27(14):147-154. DOI: 10.13422/j.cnki.syfjx.20210485.
YANG Hai-yang,WANG Guo-peng,YANG Wen-ning,et al.Simulation Analysis of Occupancy Rates of Baicalein, Quercetin and Galangin on Target Sites of Xanthine Oxidase[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(14):147-154. DOI: 10.13422/j.cnki.syfjx.20210485.
目的
2
模拟分析黄芩素、槲皮素、高良姜素对黄嘌呤氧化酶体内靶点占有率。
方法
2
通过体外酶促反应测定非布司他、黄芩素、槲皮素、高良姜素对黄嘌呤氧化酶的半数抑制浓度(IC
50
),利用分子对接技术对其结合自由能进行预测,同时,采用表面等离子共振技术测定其结合速率常数(k
on
)和解离速率常数(k
off
)。基于测定的结合动力学参数和提取的药物代谢动力学数据建立体内靶点占有率模型。
结果
2
非布司他、黄芩素、槲皮素、 高良姜素对黄嘌呤氧化酶的IC
50
分别为0.002 7,1.63,0.38,1.59 µmol·L
-1
,非布司他的IC
50
与文献报道一致。预测的非布司他体内靶点占有率曲线与其临床药效持续时间相吻合。当大鼠按100 mg·kg
-1
单次灌胃给予槲皮素长循环脂质体时,体内靶点占有率
>
70%的持续时间约3.9 h;当大鼠按200 mg·kg
-1
单次口服给予黄芩素和高良姜素时,体内靶点占有率
>
50%的持续时间分别约为10,1.7 h。
结论
2
利用药靶结合动力学和体内药代动力学曲线建立的黄嘌呤氧化酶靶点占有率预测模型能有效地评估化合物对靶点的体内抑制活性。
Objective
2
To simulate the occupancy rates of baicalein, quercetin and galangin on the target sites of xanthine oxidase
in vivo
.
Method
2
In this experiment, the half inhibitory concentration (IC
50
) of febuxostat, baicalein, quercetin and galangin against xanthine oxidase were determined by
in vitro
enzymatic reaction. Binding free energy was predicted by molecular docking technology and their association rate constant (k
on
) and dissociation rate constant (k
off
) were determined by surface plasmon resonance technology. Based on measured binding kinetic parameters (k
on
and k
off
) and extracted pharmacokinetic data, the target occupancy model
in vivo
was established.
Result
2
The IC
50
values of febuxostat, baicalein, quercetin and galangin were 0.002 7, 1.63, 0.38, 1.59 µmol·L
-1
, respectively. The IC
50
of febuxostat was very close to that reported in the literature. The predicted curve of target occupancy rate
in vivo
of febuxostat was consistent with its duration of clinical efficacy. When single intragastric administration of long-circulating liposomes of quercetin with dose of 100 mg·kg
-1
in rats, the time of target occupancy rate
>
70%
in vivo
lasted for about 3.9 h. When rats were orally administered baicalein and galangin with dose of 200 mg·kg
-1
, the time of target occupancy rate
>
50%
in vivo
lasted for about 10 h and 1.7 h, respectively.
Conclusion
2
The prediction model of xanthine oxidase target occupancy constructed by drug target binding kinetics and
in vivo
pharmacokinetic curves can effectively evaluate the
in vivo
inhibitory activity of compounds against the target.
曾小峰 , 陈耀龙 . 2016中国痛风诊疗指南 [J]. 浙江医学 , 2017 , 39 ( 21 ): 1823 - 1832 .
杨振博 , 张肖敏 , 赵梦慧 . 中医药治疗痛风研究概述 [J]. 光明中医 , 2020 , 35 ( 15 ): 2425 - 2428 .
梁晖 , 张意侗 , 解纪惠 , 等 . 急性痛风性关节炎的中药治疗进展 [J]. 中国中医急症 , 2019 , 28 ( 3 ): 553 - 556 .
彭磊 . 基于数据挖掘的国医大师治疗痛风用药规律研究 [J]. 河南中医 , 2020 , 40 ( 10 ): 1515 - 1518 .
吴双 . 基于数据挖掘的赵进喜教授治疗高尿酸血症经验总结 [D]. 北京 : 北京中医药大学 , 2018 .
张涵雨 , 李艳 . 国医大师李济仁治疗痹病用药规律分析 [J]. 中医学报 , 2020 , 35 ( 1 ): 99 - 104 .
兰月 . 高良姜抗痛风活性部位研究 [D]. 武汉 : 中南民族大学 , 2019 .
张玉萍 . 黄芩巧治关节痛 [J]. 上海中医药杂志 , 2006 , 40 ( 8 ): 50 - 51 .
姚譞 , 何枢衡 , 唐英 . 金钱草抗痛风活性组分的提取分离及药效筛选 [J]. 中国现代中药 , 2014 , 16 ( 12 ): 985 - 988,995 .
国家药典委员会 . 中华人民共和国药典:一部 [M]. 北京 : 中国医药科技出版社 , 2015 .
ZHU J X , WANG Y , KONG L D , et al . Effects of Biota orientalis extract and its flavonoid constituents,quercetin and rutin on serum uric acid levels in oxonate-induced mice and xanthine dehydrogenase and xanthine oxidase activities in mouse liver [J]. J Ethnopharmacol , 2004 , 93 : 133 - 140 .
陈海青 , 周璇 , 王秀秀 . 槲皮素治疗高尿酸血症的机制研究 [J]. 光明中医 , 2019 , 34 ( 9 ): 1340 - 1344 .
MENG X , MAO Z , LI X , et al . Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice [J]. Oncotarget , 2017 , 8 ( 25 ): 40305 - 40317 .
ELION G B . The purine path to chemotherapy (nobel lecture) [J]. Angew Chem Int Edit , 1989 , 28 ( 7 ): 870 - 878 .
COPELAND R A . The drug-target residence time model:a 10-year retrospective [J]. Nat Rev Drug Discov , 2016 , 15 ( 2 ): 87 - 95 .
WALKUP G K , YOU Z P , ROSS P L , et al . Translating slow-binding inhibition kinetics into cellular and in vivo effects [J]. Nat Chem Biol , 2015 , 11 ( 6 ): 416 - 423 .
GEORGI V , SCHIELE F , BERGER B T , et al . Binding kinetics survey of the drugged kinome [J]. J Am Chem Soc , 2018 , 140 ( 46 ): 15774 - 15782 .
WILLEMSEN-SEEGERS N , UITDEHAAG J C M , PRINSEN M B W , et al . Compound selectivity and target residence time of kinase inhibitors studied with surface plasmon resonance [J]. J Mol Biol , 2017 , 429 ( 4 ): 574 - 586 .
The United States Pharmacopeial Convention . The United States Pharmacopeia [M]. 39 th edition . Washington : US Pharmacopeia Origination Press , 2016 .
Pharmaceuticals and Medical Devices Agency of Japan . The Japanese Pharmacopoeia [M]. 17 th edition . Tokyo : The Ministry of Health , Labor and Welfare , 2016 .
ŠMELCEROVIĆ A , TOMOVIĆ K , ŠMELCEROVIĆ Ž , et al . Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties,predicted pharmacokinetics and toxicity [J]. Eur J Med Chem , 2017 , 135 : 491 - 516 .
CHANDU B R , KANALA K , HWISA N T , et al . Bioequivalance and pharmacokinetic study of febuxostat in human plasma by using LC-MS/MS with liquid liquid extraction method [J]. Springerplus , 2013 , 2 ( 1 ): 194 .
王刚 , 杜士明 , 常明泉 , 等 . 槲皮素长循环纳米脂质体的制备及大鼠体内药动学参数测定 [J]. 医药导报 , 2012 , 31 ( 10 ): 1275 - 1278 .
张瑜 , 张富赓 , 张少强 , 等 . 芪苈强心胶囊中芥子碱硫氰酸盐、槲皮素和山柰酚在大鼠体内的药动学研究 [J]. 中国药房 , 2019 , 30 ( 15 ): 2042 - 2046 .
何秀琼 , 裴利霞 , 王一涛 , 等 . 高效液相色谱法研究大鼠灌胃黄芩素的药动学 [J]. 中国医院药学杂志 , 2010 , 30 ( 22 ): 1901 - 1905 .
李建梅 , 霍仕霞 , 高莉 , 等 . 不同纯度高良姜素的药代动力学比较研究 [J]. 中国药理学通报 , 2012 , 28 ( 9 ): 1307 - 1310 .
何翊 . 槲皮素及其衍生物在Caco-2细胞模型上的吸收机制的研究 [D]. 南昌 : 南昌大学 , 2015 .
LEMAŃSKA K , SZYMUSIAK H , TYRAKOWSKA B , et al . The influence of pH on antioxidant properties and the mechanism of antioxidant action of hydroxyflavones [J]. Free Radical Bio Med , 2001 , 31 ( 7 ): 869 - 881 .
梁然 , 陈长慧 , 艾希成 , 等 . 黄芩素与黄芩苷抗氧化活性差异的结构原因 [J]. 波谱学杂志 , 2010 , 27 ( 1 ): 132 - 140 .
RODGERS T , ROWLAND M . Physiologically based pharmacokinetic modelling 2:predicting the tissue distribution of acids,very weak bases,neutrals and zwitterions [J]. J Pharm Sci , 2006 , 95 ( 6 ): 1238 - 1257 .
RODGERS T , LEAHY D , ROWLAND M . Physiologically based pharmacokinetic modeling 1:predicting the tissue distribution of moderate-to-strong bases [J]. J Pharm Sci , 2005 , 94 ( 6 ): 1259 - 1276 .
JAISWAL J V , WADEGAONKAR P A , HAJARE S W . The bioflavonoid galangin suppresses the growth of ehrlich ascites carcinoma in Swiss Albino mice:a molecular insight [J]. Appl Biochem Biotech , 2012 , 167 ( 5 ): 1325 - 1339 .
KHOSRAVAN R , KUKULKA M J , WU J T , et al . The effect of age and gender on pharmacokinetics,pharmacodynamics,and safety of febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase [J]. J Clin Pharmacol , 2008 , 48 ( 9 ): 1014 - 1024 .
TANG Y H , ZHU H Y , ZHANG Y Y , et al . Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography [J]. Biomed Chromatogr , 2006 , 20 ( 10 ): 1116 - 1119 .
BOULTON D W , WALLE U K , Walle T . Extensive binding of the bioflavonoid quercetin to human plasma proteins [J]. J Pharm Pharmacol , 1998 , 50 ( 2 ): 243 - 249 .
WANG G , JI Y , LI X , et al . Utilizing the combination of binding kinetics and micro-pharmacokinetics link in vitro α -glucosidase inhibition to in vivo target occupancy [J]. Biomolecules , 2019 , 9 ( 9 ): 493 .
Pharmaceuticals and Medical Devices Agency . Report on the deliberation results [EB/OL].( 2016-04-04 )[ 2020-10-28 ]. https://www.pmda.go.jp/files/000223355.pdf https://www.pmda.go.jp/files/000223355.pdf
MATSUMOTO K , OKAMOTO K , ASHIZAWA N , et al . FYX-051:a novel and potent hybrid-type inhibitor of xanthine oxidoreductase [J]. J Pharmacol Exp Ther , 2011 , 336 ( 1 ): 95 - 103 .
OKAMOTO K , EGER B T , NISHINO T , et al . An extremely potent inhibitor of xanthine oxidoreductase.Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition [J]. J Biol Chem , 2003 , 278 ( 3 ): 1848 - 1855 .
COPELAND R A . Evaluation of Enzyme Inhibitors in Drug Discovery:A Guide for Medicinal Chemists and Pharmacologists [M]. 2 nd edition . New York : John Wiley & Sons,Inc , 2013 .
LU H , TONGE P J . Drug-target residence time:critical information for lead optimization [J]. Curr Opin Chem Biol , 2010 , 14 ( 4 ): 467 - 474 .
刘志宝 , 吴耽 , 唐娟 , 等 . 辛芍组方效应成分在正常和脑缺血再灌注损伤大鼠肝微粒体中的酶促反应动力学分析 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 1 ): 169 - 176 .
COPELAND R A . The drug-target residence time model:a 10-year retrospective [J]. Nat Rev Drug Discov , 2016 , 15 ( 2 ): 87 - 95 .
0
Views
21
下载量
1
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621